Single Radiotherapy Fraction with Local Anti-CD40 Therapy Generates Effective Abscopal Responses in Mouse Models of Cervical Cancer.
abscopal effect
anti-CD40
cervical cancer
immunotherapy
in situ vaccination
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
03
03
2020
revised:
04
04
2020
accepted:
20
04
2020
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
26
4
2020
Statut:
epublish
Résumé
Current treatment options for advanced cervical cancer are limited, especially for patients in poor-resource settings, with a 17% 5-year overall survival rate. Here, we report results in animal models of advanced cervical cancer, showing that anti-CD40 therapy can effectively boost the abscopal effect, whereby radiotherapy of a tumor at one site can engender therapeutically significant responses in tumors at distant untreated sites. In this study, two subcutaneous cervical cancer tumors representing one primary and one metastatic tumor were generated in each animal. Only the primary tumor was treated and the responses of both tumors were monitored. The study was repeated as a function of different treatment parameters, including radiotherapy dose and dosing schedule of immunoadjuvant anti-CD40. The results consistently suggest that one fraction dose of radiotherapy with a single dose of agonistic anti-CD40 can generate highly effective abscopal responses, with a significant increase in animal survival (
Identifiants
pubmed: 32331490
pii: cancers12041026
doi: 10.3390/cancers12041026
pmc: PMC7226489
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA239042
Pays : United States
Organisme : NIH HHS
ID : R01CA239042
Pays : United States
Références
Radiat Res. 2014 Aug;182(2):170-81
pubmed: 24937779
Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1246-1253
pubmed: 29395628
J Immunol. 2005 Jan 1;174(1):41-50
pubmed: 15611226
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Cancer Immunol Res. 2018 Feb;6(2):139-150
pubmed: 29180535
Cancer Manag Res. 2017 Oct 31;9:553-563
pubmed: 29184441
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Phys Med Biol. 2016 Dec 21;61(24):N697-N707
pubmed: 27910826
Oncologist. 2019 Feb;24(Suppl 1):S42-S52
pubmed: 30819830
Gynecol Oncol Rep. 2017 Sep 01;22:16-20
pubmed: 28948205
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165
Theranostics. 2016 Jan 01;6(3):328-41
pubmed: 26909109
Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186
pubmed: 27927088
Front Oncol. 2018 Mar 12;8:56
pubmed: 29594038
JCO Glob Oncol. 2020 Apr;6:667-678
pubmed: 32343628
Cancer Immunol Immunother. 2016 Feb;65(2):127-39
pubmed: 26660339
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
Front Immunol. 2018 Sep 07;9:2030
pubmed: 30245691
Cancer. 2017 Dec 15;123 Suppl 24:5119-5137
pubmed: 29205300
JAMA Oncol. 2018 Apr 1;4(4):514-515
pubmed: 29423514